Client News

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab

Formycon Invites to Earnings Call on the Nine-Month Results 2024 and Announces Participation in International Investor Conferences

Formycon Receives Positive CHMP Opinion for FYB203 (Aflibercept), a Biosimilar Candidate to Eylea® under the Tradenames AHZANTIVE® and Baiama®

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Abivax Presents Third Quarter 2024 Key Financial Information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Andera Partners Continues its International Expansion and Announces the Opening of a Madrid Office

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Medigene AG Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024

Formycon Extends Management Board Contract for CEO Dr. Stefan Glombitza until 2027 and Receives Admission to Trading in the Prime Standard